Immunologiya最新文献

{"title":"Changes in the functional properties of dendritic cells upon contact with microorganisms of the genera Bacillus, Lactiplantibacillus and Limosilactobacillus","authors":"V. Talayev, I. Zaichenko, M. Svetlova, E. Voronina, O. Babaykina, I. Soloveva, I. Belova, A. G. Tochilina","doi":"10.33029/0206-4952-2022-43-5-504-514","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-5-504-514","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Сontroversial role of innate immunity factors in impaired fertility in men affected by varicocele","authors":"E. Khasanova, L. Gankovskaya, V. Grechenko","doi":"10.33029/0206-4952-2022-43-1-61-70","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-1-61-70","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of criteria for immobilization of human erythrocytes of phenotypes R1R1 and R2R2 on the solid phase in determining the content of anti-D-antibodies IgG in immunoglobulin human antirhesus Rho(D) preparations by enzyme immunoassay","authors":"E. Shvedova, S. A. Leshina, D. S. Davydov, I. Borisevich, E. Kudasheva","doi":"10.33029/0206-4952-2022-43-2-208-216","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-2-208-216","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The proteins of γ-globulin fraction, that bind metal ions, in physiological immune regulation. Polarization of the responses and rational limitation of inflammation","authors":"S. B. Cheknev","doi":"10.33029/0206-4952-2022-43-4-468-476","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-4-468-476","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reprogramming of myeloid cells of the tumor microenvironment increases the efficiency of CTLA-4 and PD-1 blockade in experimental malignant melanoma immunotherapy","authors":"A. Pichugin, S.A. Podsvirova, E. Ushakova, D.M. Spirin, E. Lebedeva, R. Ataullakhanov","doi":"10.33029/0206-4952-2022-43-6-673-690","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-6-673-690","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of specific humoral response in COVID-19 patients","authors":"V. Zakurskaya, L. Sizyakina, M. Kharitonova, S. Shlyk","doi":"10.33029/0206-4952-2022-43-1-71-77","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-1-71-77","url":null,"abstract":"Introduction. The pandemic caused by the SARS-CoV-2 virus is an important medical and social problem. It remains unclear the stability of the developed humoral immunity against the SARS-CoV-2 virus, the average duration of preservation of the titer of specific antibodies. The need to identify humoral mechanisms of immune defense in patients with COVID-19 determined the purpose of this study. The aim of the study – to evaluate the dynamics of changes in the content of specific IgG antibodies against various antigens of the SARS-CoV-2 virus and B-lymphocyte subpopulations throughout the year in people who have had COVID-19. Material and methods. The study included 90 patients who had undergone COVID-19 in various forms, subsequently divided into 2 groups: persons with asymptomatic and mild course (57 patients) and with moderate or severe course of the disease (33 patients). The dynamics of the concentration of specific antibodies to the SARS-CoV-2 virus was evaluated by enzyme immunoassay every 3 months for a year. The content of the total pool B-lymphocytes (naive B-lymphocytes, memory B-cells, regulatory B-lymphocytes) and various subpopulations was evaluated by flow cytofluorimetry. Results. When assessing the dynamics of IgG to the S-protein of the SARS-CoV-2 virus, their preservation was noted by the 12th month after recovery. In patients with severe and moderate COVID-19 forms, these indicators are significantly higher. More severe forms of COVID-19 are accompanied by significantly higher content level of memory B cells throughout the observation period. Conclusion. Moderate and severe forms of COVID-19 induce more persistent postinfectious humoral immunity, provided by an increase in memory B cells in comparison with lighter forms.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood B-lymphocyte subpopulations coexpressing CD5 and chemokine receptors in patients with chronic obstructive pulmonary disease","authors":"A. Kadushkin, A. Tahanovich, L. Movchan, M. Zafranskaya, V. Dziadzichkina, T. Shman","doi":"10.33029/0206-4952-2022-43-2-197-207","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-2-197-207","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic and functional characteristic analysis of THP-1 cell line as a model of inflammation","authors":"E. Kokinos, D. Kuzmina, O. Kuchur, S. Tsymbal, V. A. Vasilichin, A. V. Galochkina, A.V. Zavirskyi, V. Basharin, A. Shtro, A. Shtil, M. Dukhinova","doi":"10.33029/0206-4952-2022-43-3-277-287","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-3-277-287","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Features of postinfectious immunity formation in a patient with common variable immune deficiency and severe COVID-19 course: a description of a clinical case","authors":"L. Sizyakina, I. Andreeva, N. Skripkina","doi":"10.33029/0206-4952-2022-43-4-440-446","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-4-440-446","url":null,"abstract":"Background. Common variable immune deficiency (CVID) is a complicating comorbid background of COVID-19. Post-infectious immunity formation to SARS-CoV-2 during a pandemic is of particular relevance for such patients. Aim of the study - to present the features of the development of postinfectious humoral immune response in a patient with CVID. Material and methods. Patient K., 49 years old, the diagnosis of CVID verified at the age of 33, has been receiving regular replacement therapy with intravenous immunoglobulins for the last 10 years. After intrafamily contact and infection with SARS-CoV-2 due to the progressive deterioration of the clinical course of COVID-19, he was admitted to a monoinfection hospital. Results. During the treatment of the severe clinical case of COVID-19 a patient with CVID proved to be effective therapy combining anti-cytokine drugs and additional courses of replacement therapy with intravenous immunoglobulins. 6 weeks later from the development of the clinic, the patient was detected specific antibodies to SARS-CoV-2 antigens - IgM (CP 4.73) and IgG (43 BAU), in 4 months the corresponding parameters were 3.55 (CP IgM) and 487 BAU (CP IgG). Comparative analysis of immunophenotyping of the patient's B lymphocytes before the disease, during periods of early and late convalescence showed the dynamics of changes in the number of naive B-lymphocytes, unswitched and switched B-memory cells, plasmablasts, B-reg and B-lymphocytes expressing intercellular cooperation molecules. Conclusion. In the patient with CVID the development of a specific humoral immune response to SARS-CoV-2 after a COVID-19 infection is accompanied by an increase in the proportion of B-memory cells, increased maturation of B-lymphocytes, coordinated dynamics of B-cell suppression and activation parameters. Copyright © 2022 Authors. All rights reserved.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19","authors":"A. Soldatov, Z. Avdeeva, D. Gorenkov, L. M. Khantimirova, Yu.S. Paramonova, E.M. Smolina, V. Bondarev, V. A. Merkulov","doi":"10.33029/0206-4952-2022-43-5-485-503","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-5-485-503","url":null,"abstract":"The development of the COVID-19 pandemic initiated the search for effective drugs for the treatment and prevention of infection. Of particular importance for the fight against the pandemic is the timing of the introduction of drugs into clinical practice. Therefore, countries with developed healthcare systems (EU, USA, Russian Federation, etc.), issue conditional marketing authorizations of drugs for treatment and prevention of COVID-19, based on regulatory requirements for the circulation of medicines in emergency situations. The approval is issued on the basis of limited clinical data, with the condition that the full evaluation of safety and effectiveness will be carried out after the issuance of the authorization in the post-registration period. The COVID-19 pandemic has revolutionized the design and time frame of clinical trials, including phase I, II, and III adaptive trials, which has led to the approval of biologics for the treatment and prevention of COVID-19 in record time in most advanced pharmaceutical countries. At the same time, regulatory/healthcare authorities or international organizations constantly monitor the safety and effectiveness of used drugs and, if necessary, make adjustments (changes to the indications for use, dosage change, drug discontinuation etc.). Since the beginning of the pandemic, in fact, in conditions where the use of medicines was allowed based on very limited data, studies have begun to substantiate the safety and effectiveness of the use of immunoglobulin preparations and monoclonal antibodies for the treatment and prevention of COVID-19. As new data became available, changes were made regarding the indications for use, doses, and other characteristics of preparations of immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19. The review presents a critical analysis of the results of evaluation the safety and effectiveness of the use of immunoglobulin preparations and monoclonal antibodies in a pandemic. Copyright © 2022 Meditsina Publishers. All rights reserved.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}